Literature DB >> 1357597

The selective A2 adenosine receptor agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex.

M H O'Regan1, R E Simpson, L M Perkins, J W Phillis.   

Abstract

The effects of the selective adenosine A2 receptor agonist 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamido adenosine hydrochloride (CGS 21680) on aspartate and glutamate release from the ischemic rat cerebral cortex were studied with the cortical cup technique. Cerebral ischemia (20 min) was elicited by four vessel occlusion. Pretreatment with CGS 21680 failed to alter basal excitatory amino acid levels, however, CGS 21680 at 10(-6) M significantly enhanced the ischemia-evoked release. Thus, aspartate and glutamate release during ischemia can be stimulated via the activation of A2 receptors, in addition to the suppression of excitatory amino acid release mediated by selective A1 receptor agonists.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357597     DOI: 10.1016/0304-3940(92)90498-v

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  17 in total

1.  A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice.

Authors:  J F Chen; Z Huang; J Ma; J Zhu; R Moratalla; D Standaert; M A Moskowitz; J S Fink; M A Schwarzschild
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

2.  The adenosine receptor agonist, APNEA, increases calcium influx into rat cortical synaptosomes through N-type channels associated with A2a receptors.

Authors:  S N Li; P T Wong
Journal:  Neurochem Res       Date:  2000-04       Impact factor: 3.996

3.  Continuous adenosine A2A receptor antagonism after focal cerebral ischemia in spontaneously hypertensive rats.

Authors:  Ulrike Fronz; Alexander Deten; Frank Baumann; Alexander Kranz; Sarah Weidlich; Wolfgang Härtig; Karen Nieber; Johannes Boltze; Daniel-Christoph Wagner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-10-30       Impact factor: 3.000

4.  Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.

Authors:  Silva Fredduzzi; Rosario Moratalla; Angela Monopoli; Beatriz Cuellar; Kui Xu; Ennio Ongini; Francesco Impagnatiello; Michael A Schwarzschild; Jiang-Fan Chen
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

5.  Effect of A2A adenosine receptor stimulation and antagonism on synaptic depression induced by in vitro ischaemia in rat hippocampal slices.

Authors:  S Latini; F Bordoni; R Corradetti; G Pepeu; F Pedata
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

6.  Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices.

Authors:  S Latini; F Bordoni; F Pedata; R Corradetti
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

Review 7.  Targeting astrocytes for stroke therapy.

Authors:  Yanxin Zhao; David A Rempe
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

8.  Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist.

Authors:  D K Von Lubitz; R C Lin; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1995-12-20       Impact factor: 4.432

9.  ADORA2A polymorphism predisposes children to encephalopathy with febrile status epilepticus.

Authors:  Mayu Shinohara; Makiko Saitoh; Daisuke Nishizawa; Kazutaka Ikeda; Shinichi Hirose; Jun-ichi Takanashi; Junko Takita; Kenjiro Kikuchi; Masaya Kubota; Gaku Yamanaka; Takashi Shiihara; Akira Kumakura; Masahiro Kikuchi; Mitsuo Toyoshima; Tomohide Goto; Hideo Yamanouchi; Masashi Mizuguchi
Journal:  Neurology       Date:  2013-03-27       Impact factor: 9.910

10.  Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease.

Authors:  M Morelli; J Wardas
Journal:  Neurotox Res       Date:  2001-11       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.